^
    9ms
    To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 (clinicaltrials.gov)
    P1, N=12, Recruiting, Eutilex | Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> Jun 2025
    Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • GPC3 (Glypican 3) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL18 (Interleukin 18)
    |
    EU307
    over1year
    To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Eutilex
    New P1 trial • CAR T-Cell Therapy • Metastases
    |
    GPC3 (Glypican 3)
    |
    EU307
    almost2years
    IL-18 secreting chimeric antigen receptor T cells targeting glypican-3show superior persistence and antitumor immunity against hepatocellular carcinoma (AACR 2023)
    In this regard, we report here that we have successfully developed a CAR-T cell therapy, referred to as EU307, to treat one type of solid tumor, hepatocellular carcinoma (HCC)...Furthermore, a single dose toxicity study in the same disease mouse model determined the no observed adverse effect level (NOAEL) as 5.0 X 105 total cells per male and 1.0 X 106 total cells per female. Taken together, our studies demonstrate that we have a developed a novel fourth-generation CAR-T therapy to treat HCC, a solid tumor that expresses a high-level of tumor-specific GPC3, by overcoming previously limiting factors in the development of CAR-T therapies against solid tumors.
    Late-breaking abstract • CAR T-Cell Therapy
    |
    GPC3 (Glypican 3) • IL18 (Interleukin 18)
    |
    EU307